

ANNUAL REPORT

For the Year Ended September 30, 2016

Pursuant to Rule 15c2-(11)(a)(5)

AIRWARE LABS CORP.

Dated: January 13, 2017

All information contained in this Annual Report has been compiled to fulfill the disclosure requirements of Rule 15c2-11 (a)(5) promulgated under the Securities and Exchange Act of 1934, as amended. The enumerated captions contained herein correspond to the sequential format as set forth in the rule.

AIRWARE LABS CORP.
Table of Contents

Item 1.	The Exact Name of the Issuer and its Predecessors	1
Item 2.	Address of the Issuer's Principal Executive Offices	1
Item 3.	Security Information	1
Item 4.	Issuance History	2
Item 5.	Financial Statements	5
	<i>Independent Accountant's Compilation Report</i>	
	<i>Consolidated Balance Sheets as of September 30, 2016 (Unaudited) and 2015 (Audited)</i>	
	<i>Consolidated Statements of Operations for the Years Ended September 30, 2016 (Unaudited) and 2015 (Audited)</i>	
	<i>Consolidated Statement of Changes in Stockholders' Deficit for the Years Ended September 30, 2016 (Unaudited) and 2015 (Audited)</i>	
	<i>Consolidated Statements of Cash Flows for the Years Ended September 30, 2016 (Unaudited) and 2015 (Audited)</i>	
	<i>Notes to Consolidated Financial Statements</i>	
Item 6.	Issuer's Business, Products, and Services	20
Item 7.	Issuer's Facilities	22
Item 8.	Officers, Directors, and Control Persons	22
Item 9.	Third Party Providers	24
Item 10.	Issuer Certification	25

AIRWARE LABS CORP.

Annual Disclosure Statement

All information contained in this Annual Report has been compiled to fulfill the disclosure requirements of Rule 15c2-11 (a)(5) promulgated under the Securities and Exchange Act of 1934, as amended. The enumerated captions contained herein correspond to the sequential format as set forth in the rule.

No dealer, salesman or any other person has been authorized to give any information or to make any representations not contained herein in connection with the Issuer. Any representations not contained herein must not be relied upon as having been made or authorized by the Issuer.

Delivery of this information does not imply that the information contained herein is correct as of any time subsequent to the date of this Annual Report.

ITEM 1. THE EXACT NAME OF THE ISSUER AND ITS PREDECESSORS

Airware Labs Corp. (hereinafter referred to as “Airware Labs,” “Issuer” or the “Company”)

The names and history of the Issuer’s predecessors:

The Company was incorporated in the state of Delaware under the name Crown Dynamics Corp on June 15, 2010. On October 26, 2012, the Articles of Incorporation were amended to reflect a name change to Airware Labs Corp.

On March 20, 2012, through an equity exchange agreement, the Company acquired all of the issued and outstanding stock of Airware Holdings, Inc., a Nevada corporation (“Airware”), in exchange for shares of the Company’s newly-issued common stock. Airware Holdings, Inc. was formed in February 2010 and is a non-prescription medical products company.

ITEM 2. ADDRESS OF THE ISSUER’S PRINCIPAL EXECUTIVE OFFICES

Airware Labs Corp.

7377 East Doubletree Ranch Road, Suite 260
Scottsdale, AZ 85258
Phone: 877-876-4868
Website: www.airwarelabscorp.com

Investor Relations Firm:

None

ITEM 3. SECURITY INFORMATION

Trading symbol

The Company’s trading symbol is AIRW.

The Company’s CUSIP

CUSIP for common stock is 00951F105.

Par of Stated Value:

Common Stock – Par Value \$0.0001

Shares Authorized:

The Company is authorized to issue Two Hundred Million (200,000,000) shares of common stock.

Shares Outstanding:

Common Stock

(i)	Period End Date:	September 30, 2016
(ii)	Number of shares authorized:	200,000,000
(iii)	Number of shares outstanding:	148,251,127
(iv)	Freely tradable shares (public float):	16,087,900
(v)	Total number of shareholders of record:	150

Transfer Agent

Nevada Agency and Transfer Company
50 W. Liberty St., Suite 880
Reno, NV 89501
Phone: (775) 322-0626

Restrictions on the transfer of any security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

ITEM 4. ISSUANCE HISTORY

To the best knowledge of the present management of the Company, the list identified below identifies all events, in chronological order, that resulted in changes in total shares outstanding by the Company (1) within the two-year period ending on the last day of the Company's most recent fiscal year and (2) since the last day of the Company's most recent fiscal year.

For the quarter ended September 30, 2016, a total of 70,516,469 shares of common stock were issued. The following is a breakdown of those issuances:

On August 16, 2016, the Company issued 2,740,494 shares of common stock to our primary debt holder as payment for interest on loans to the Company for April through July 2016. The Company also issued 104,258 shares of common stock for the payment of consulting services rendered to the Company between October 1, 2015 and June 30, 2016.

On September 30, 2016, the Company issued 701,200 shares of common stock to our primary debt holder as payment for interest on loans to the Company for August 2016. Additionally, the Company issued 1,036,451 shares of common stock for the payment of services to the Company. The Company also issued 65,934,066 shares of common stock to our primary debt holder in exchange for the conversion of \$3,000,000 in debt.

There have been no issuances subsequent to September 30, 2016.

For the quarter ended June 30, 2016, a total of 757,117 shares of common stock were issued. The following is a breakdown of those issuances:

On April 7, 2016, the Company issued 681,200 restricted shares of common stock to a related party as payment for interest on loans to the Company for March 2016, at a cost basis of \$0.05 per share. Additionally, the Company issued 75,917 restricted shares of common stock to two individuals as consideration for an invoice owed to their design company for services rendered to the Company at a cost basis of \$0.15 per share.

For the quarter ended March 31, 2016, a total of 2,547,587 shares of common stock were issued. The following is a breakdown of those issuances:

On March 15, 2016, the Company issued 1,930,087 restricted shares of common stock to a related party as payment for interest on loans to the Company for December 2015 through February 2016, at a cost basis of \$0.05 per share. Additionally, the Company issued 100,000 restricted shares of common stock to a shareholder at a cost basis of \$0.10 per share pursuant to a subscription agreement dated January 29, 2016. The Company also issued 517,500 restricted shares of common stock to a shareholder at a cost basis of \$0.20 per share pursuant to a Subscription Agreement dated April 10, 2015.

For the quarter ended December 31, 2015, a total of 2,219,671 shares of common stock were issued. The following is a breakdown of those issuances:

On November 5, 2015, the Company issued 641,200 restricted shares of common stock to a related party as payment for interest on loans to the Company for September 2015, at a cost basis of \$0.05 per share.

On December 31, 2015, the Company issued 1,282,400 restricted shares of common stock to a related party as payment for interest on loans to the Company for October and November 2015, at a cost basis of \$0.05 per share. Additionally, the Company issued an aggregate 200,000 restricted shares of common stock to two shareholders at a cost basis of \$0.10 per share pursuant to two subscription agreements dated between December 3, 2015 and December 14, 2015, and 96,071 restricted shares of common stock as compensation to a consultant for services rendered to the Company between April 1, 2015 and September 30, 2015. The shares were valued at the average trading price over the period of service, which approximated fair value, in the amount of \$12,750.

For the quarter ended September 30, 2015, a total of 5,102,606 shares of common stock were issued. The following is a breakdown of those issuances:

On July 9, 2015, the Company issued an aggregate of 1,892,106 restricted shares of common stock to a related party as payment for interest in the months of April-June, totaling \$94,605, on loans to the Company. Additionally, the Company issued 78,100 restricted shares of common stock in settlement of amounts owed to a consultant for services rendered to the Company, with a grant date fair value of \$19,525.

On August 26, 2015, the Company issued 641,200 restricted shares of common stock to a related party as payment for interest on loans to the Company for July 2015, at a cost basis of \$0.05 per share.

On September 30, 2015, the Company issued 641,200 restricted shares of common stock to a related party as payment for interest on loans to the Company for August 2015, at a cost basis of \$0.05 per share. Additionally, the Company issued an aggregate 1,850,000 restricted shares of common stock to three shareholders at a cost basis of \$0.10 per share pursuant to a three subscription agreements dated between August 11, 2015 and September 4, 2015.

For the quarter ended June 30, 2015, a total of 973,957 shares of common stock were issued. The following is a breakdown of those issuances:

On April 28, 2015, the Company issued 629,987 restricted shares of common stock as payment for interest totaling \$31,499 on loans to the Company for March 2015. Additionally, the Company issued 250,000 restricted shares of common stock to one shareholder for proceeds of \$50,000 pursuant to a subscription agreement dated April 10, 2015. The Company also issued 93,970 restricted shares of common stock with a grant date fair value of \$12,000 as compensation to a consultant for services rendered to the Company between January and March 31, 2015.

For the quarter ended March 31, 2015, a total of 1,865,238 shares of common stock were issued. The following is a breakdown of those issuances:

On January 28, 2015, the Company issued 599,987 restricted shares of common stock as payment for interest on loans to the Company for December 2014, at a cost basis of \$0.05 per share. Additionally, the Company issued 591,600 restricted shares of common stock as payment for interest on loans to the Company for January 2015, at a cost basis of \$0.05 per share. The Company also issued 82,051 restricted shares of common stock as payment for services rendered to the Corporation from October 31, 2014 to December 31, 2014, at a cost basis of \$0.15 per share.

On March 17, 2015, the Company issued 591,600 restricted shares of common stock as payment for interest on loans to the Company for February 2015, at a cost basis of \$0.05 per share.

For the quarter ended December 31, 2014, a total of 2,012,103 shares of common stock were issued. The following is a breakdown of those issuances:

On October 10, 2014, the Company issued 541,600 shares of restricted common stock as payment for interest on loans to the Company for September 2014, at a cost basis of \$0.05 per share.

On November 12, 2014, the Company issued 250,000 restricted shares of common stock to one holder pursuant to a Consulting Agreement dated October 13, 2014, at a cost basis of \$0.20 per share. The Company also issued 576,653 shares of restricted common stock as payment for interest on loans to the Company for October 2014, at a cost basis of \$0.05 per share. Additionally, the Company issued 72,250 restricted shares of common stock to one holder as compensation for services rendered to the Corporation from July 1, 2014 to September 30, 2014, at a cost basis of \$0.166 per share.

On December 4, 2014, the Company issued 571,600 shares of restricted common stock as payment for interest on loans to the Company for November 2014, at a cost basis of \$0.05 per share.



D. Brooks and Associates CPA's, P.A.

Certified Public Accountants • Certified Valuation Analysts

INDEPENDENT ACCOUNTANT'S COMPILATION REPORT

To the Board of Directors and Stockholders
Airware Labs Corp.
Scottsdale, Arizona

Management is responsible for the accompanying financial statements of Airware Labs Corp. (a corporation), which comprise the consolidated balance sheets as of September 30, 2016, and the related consolidated statements of operations, changes in stockholders' deficit and cash flows for the year then ended, and the related notes to the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. We have performed the compilation engagement in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. We did not audit or review the 2016 financial statements nor were we required to perform any procedures to verify the accuracy or completeness of the information provided by management. Accordingly, we do not express an opinion, a conclusion, nor provide any form of assurance on these financial statements.

The 2015 consolidated financial statements were audited by us, and (we expressed an unmodified opinion on them in our report dated March 4, 2016). We have not performed any auditing procedures since that date.

D. Brooks and Associates CPA's, P.A.

West Palm Beach, FL
January 11, 2017

**AIRWARE LABS CORP. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, 2016 AND 2015**

	2016	2015
	(Unaudited)	(Audited)
<u>ASSETS</u>		
Current Assets:		
Cash and cash equivalents	\$ 26,709	\$ 41,745
Accounts receivable	44,352	530
Inventory, net	5,704	45,457
Prepaid expenses and other current assets	5,921	8,476
Total current assets	<u>82,686</u>	<u>96,208</u>
Other Assets:		
Property and equipment, net	4,142	14,070
Deposits	2,387	2,387
Total Assets	<u><u>\$ 89,215</u></u>	<u><u>\$ 112,665</u></u>
<u>LIABILITIES AND STOCKHOLDERS' DEFICIT</u>		
Current Liabilities:		
Accounts payable	\$ 1,692,057	\$ 1,640,327
Accrued interest - related parties	43,215	38,849
Accrued interest	2,044	1,644
Accrued expenses	89,744	138,057
Note payable to former officer	8,788	47,500
Convertible notes payable - current portion	5,000	5,000
Convertible notes payable to related parties - current portion, net of discount	321,530	20,000
Total current liabilities	<u>2,162,378</u>	<u>1,891,377</u>
Convertible notes payable to related parties, less current portion	<u>-</u>	<u>3,206,000</u>
Total liabilities	<u><u>2,162,378</u></u>	<u><u>5,097,377</u></u>
Commitments and Contingencies		
Stockholders' Deficit:		
Common stock, par value \$.0001 per share, 200,000,000 shares authorized; 148,251,127 and 72,210,283 shares issued and outstanding at September 30, 2016 and 2015, respectively	14,825	7,221
Common stock to be issued, 133,916 and 290,000 shares at September 30, 2016 and 2015, respectively	13	29
Additional paid-in capital	37,873,132	31,843,635
Accumulated deficit	(39,961,133)	(36,835,597)
Total stockholders' deficit	<u>(2,073,163)</u>	<u>(4,984,712)</u>
Total Liabilities and Stockholders' Deficit	<u><u>\$ 89,215</u></u>	<u><u>\$ 112,665</u></u>

See independent accountant's compilation report and notes to the consolidated financial statements.

AIRWARE LABS CORP. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED SEPTEMBER 30, 2016 AND 2015

	2016	2015
	(Unaudited)	(Audited)
Revenues, net	\$ 324,026	\$ 113,022
Cost of products sold	158,322	117,306
Gross profit (loss)	<u>165,704</u>	<u>(4,284)</u>
Operating expenses:		
General and administrative	729,382	869,649
Sales and marketing	42,210	241,944
Total operating expenses	<u>771,592</u>	<u>1,111,593</u>
Loss from operations	<u>(605,888)</u>	<u>(1,115,877)</u>
Other expense:		
Interest expense	(992,175)	(2,961,153)
Loss on deposits	-	(21,529)
Bad debt expense	(530)	-
Loss on impairment of intangible assets	-	(249,180)
Loss on extinguishment of debt	(1,526,943)	(392,945)
Total other expense	<u>(2,519,648)</u>	<u>(3,624,807)</u>
Loss before income taxes	(3,125,536)	(4,740,684)
Income taxes	<u>-</u>	<u>-</u>
Net loss	<u>\$ (3,125,536)</u>	<u>\$ (4,740,684)</u>
Basic and diluted net loss per common share	<u>\$ (0.04)</u>	<u>\$ (0.07)</u>
Basic and diluted weighted average common shares outstanding	<u>76,276,879</u>	<u>66,406,701</u>

See independent accountant's compilation report and notes to the consolidated financial statements.

AIRWARE LABS CORP. AND SUBSIDIARY
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT
YEARS ENDED SEPTEMBER 30, 2016 (UNAUDITED) AND 2015 (AUDITED)

	Common Stock		Additional	Common Stock	Accumulated	
	Shares	Amount	Paid-in	to be	Deficit	Total
			Capital	Issued		
Balance at September 30, 2014	62,256,379	\$ 6,226	\$29,452,379	\$ -	\$ (32,094,913)	\$(2,636,308)
Issuance of stock for cash	2,100,000	210	271,161	29	-	271,400
Exchange of shares for services	498,271	50	85,951	-	-	86,001
Shares issued in settlement of accounts payable	78,100	7	19,517	-	-	19,524
Exchange of shares for interest expense - related party	7,277,533	728	1,051,251	-	-	1,051,979
Stock options issued for services	-	-	68,438	-	-	68,438
Warrants issued for services	-	-	3,993	-	-	3,993
Discount of convertible notes - related party	-	-	498,000	-	-	498,000
Warrants issued for debt extinguishment - related party	-	-	392,945	-	-	392,945
Net loss	-	-	-	-	(4,740,684)	(4,740,684)
Balance at September 30, 2015	72,210,283	7,221	31,843,635	29	(36,835,597)	(4,984,712)
Issuance of stock for cash	817,500	82	63,347	(29)	-	63,400
Exchange of shares for services	1,312,697	131	133,900	13	-	134,044
Exchange of shares for interest expense - related party	7,976,581	798	889,829	-	-	890,627
Stock options issued for services	-	-	115,213	-	-	115,213
Warrants issued for services	-	-	6,858	-	-	6,858
Shares issued for conversion of notes payable - related party	65,934,066	6,593	2,993,407	-	-	3,000,000
Discount on convertible notes - related party	-	-	300,000	-	-	300,000
Loss on extinguishment of debt	-	-	1,526,943	-	-	1,526,943
Net loss	-	-	-	-	(3,125,536)	(3,125,536)
Balance at September 30, 2016	<u>148,251,127</u>	<u>\$ 14,825</u>	<u>\$37,873,132</u>	<u>\$ 13</u>	<u>\$ (39,961,133)</u>	<u>\$(2,073,163)</u>

See independent accountant's compilation report and notes to the consolidated financial statements.

AIRWARE LABS CORP. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED SEPTEMBER 30, 2016 AND 2015

	2016	2015
	(Unaudited)	(Audited)
Operating Activities:		
Net loss	\$ (3,125,536)	\$ (4,740,684)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	9,928	64,480
Common stock issued/obligated for services	134,044	86,001
Options and warrants issued for services	122,071	72,431
Loss on impairment of intangible assets	-	249,180
Interest expense from amortization of debt discount	95,530	1,901,341
Stock issued for payment of interest on convertible notes - related party	890,627	1,051,979
Exchange of sales proceeds for mold	-	(8,290)
Loss on extinguishment of debt	1,526,943	392,945
Changes in operating assets and liabilities:		
Accounts receivable	(43,822)	2,607
Inventory	39,753	26,157
Prepaid expenses	2,555	57,729
Deposits	-	10,000
Accounts payable	51,730	20,323
Accrued interest	4,766	7,067
Accrued expenses	(48,313)	65,885
Net Cash Used in Operating Activities	(339,724)	(740,849)
Investing Activities:		
Purchases of property and equipment	-	(6,710)
Net Cash Used in Investing Activities	-	(6,710)
Financing Activities:		
Stock and warrants issued for cash	63,400	271,400
Proceeds from convertible notes payable - related party	300,000	498,000
Repayment of notes payable to former officer	(38,712)	-
Repayment of notes payable	-	(22,678)
Net Cash Provided by Financing Activities	324,688	746,722
Net Decrease in Cash	(15,036)	(837)
Cash - Beginning of Year	41,745	42,582
Cash - End of Year	\$ 26,709	\$ 41,745
Supplemental disclosure of cash flow information:		
Interest paid in cash	\$ 663	\$ 292
Income taxes paid in cash	\$ -	\$ -
Non-cash investing and financing activities:		
Stock issued for convertible notes	\$ 3,000,000	\$ -
Debt discount on note payable, related party	\$ 300,000	\$ 498,000
Stock issued in settlement of accounts payable	\$ -	\$ 19,524
Warrants issued to related party for convertible note modification	\$ 108,140	\$ 392,945
Credit towards manufacturing mold from factory	\$ -	\$ 8,290

See independent accountant's compilation report and notes to the consolidated financial statements.

AIRWARE LABS CORP. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1 - Summary of Significant Accounting Policies

Basis of Presentation and Organization

Airware Labs Corp. (“Airware Labs” or the “Company”), formerly Crown Dynamics Corp., is a Delaware corporation. The Company was incorporated under the laws of the State of Delaware on June 15, 2010. On October 26, 2012, the Articles of Incorporation were amended to reflect a name change to Airware Labs Corp.

On March 20, 2012, through an equity exchange agreement, the Company acquired all of the issued and outstanding stock of Airware Holdings, Inc., a Nevada corporation (“Airware”), in exchange for shares of the Company’s newly-issued common stock. Airware Holdings, Inc. was formed in February 2010 and is a non-prescription medical products company. The principal business purpose of the Company is to develop, manufacture and distribute breathing solutions that address major respiratory challenges impacting human health.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Airware Labs Corp and its wholly owned subsidiary, Airware Holdings, Inc. Intercompany balances and transactions have been eliminated.

Accounting Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. Significant estimates of the Company include accounting for depreciation, deferred income taxes, accruals and contingencies, estimates for customer returns, the fair value of common stock and the estimated fair value of stock options and warrants.

Cash and Cash Equivalents

The Company considers all highly liquid instruments purchased with a remaining maturity of three months or less to be cash equivalents.

Accounts Receivable

The Company follows the allowance method of recognizing uncollectible accounts receivable. The allowance method recognizes bad debt expense based on a review of the individual accounts outstanding and the Company’s prior history of uncollectible accounts receivable. As of September 30, 2016 and 2015, no allowance was established for potentially uncollectible accounts receivable as none was deemed necessary. During the years ended September 30, 2016 and 2015, the Company had bad debt expense totaling \$530 and \$0, respectively. The Company had sales returns totaling \$18,674 and \$31,177 for the years ended September 30 2016 and 2015, respectively. As of September 30, 2016 and 2015, the allowance for sales returns was \$5,000 and \$13,000, respectively. The Company’s policy is to record finance charges on outstanding delinquent accounts receivable only if they are collected. Accounts receivable are generally unsecured.

Inventory

Inventory is mostly held by a third party, consists of finished goods and is stated at the lower of cost, determined by the first-in, first-out method, or market.

Property and Equipment

Property and equipment are recorded at cost. Depreciation is provided for on the straight-line method, over the estimated useful lives of the assets. Maintenance and repairs that neither materially add to the value of the property nor appreciably prolong its life are charged to expense as incurred. Betterments or renewals are capitalized when incurred. Gains and losses on the disposition of property and equipment are recorded in the period incurred. Production molds owned by the Company are capitalized and are included in manufacturing equipment. Pre-production design and development costs are expensed as incurred.

The estimated useful lives of property and equipment are:

- | | |
|----------------------------------|-----------|
| • Manufacturing equipment | 2-3 years |
| • Office furniture and equipment | 5-7 years |

Income Taxes

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse.

On an on-going basis, the Company assesses the likelihood that the deferred tax assets will be recovered from future taxable income. At September 30, 2016 and 2015, it was believed that the recovery of the deferred tax assets was less than likely and therefore, a full valuation allowance was established.

Interest relative to income taxes is charged to interest expense and penalties are charges to general and administrative costs if there are any assessments. No interest or penalties relative to income taxes have been recognized during the years ended September 30, 2016 or 2015.

The Company files income tax returns in the U.S. federal jurisdiction, and the State of Arizona. The Company is subject to U.S. federal, state, and local income tax examinations by tax authorities. All periods beginning on or after January 1, 2013 are open to examination by taxing authorities. The Company believes it has no tax positions for which the ultimate deductibility is highly uncertain.

Revenue Recognition

The Company recognizes revenue on the sale of products at the time of delivery and acceptance. Delivery is generally FOB destination. At the time of delivery, the following have occurred:

- Evidence of delivery;
- A price per unit has been determined; and
- Collectability has been reasonably assured.

Revenues are recorded net of returns and co-operative advertising costs.

Fair Value of Financial Instruments

The carrying value of the Company's financial instruments, consisting of cash, accounts payable, convertible notes payable to third parties, and related party notes payable to former officer, approximate fair value due to their short term to maturity. The carrying value of the Company's related party convertible debt approximates fair value due to the terms that are similar to current market rates.

Net Loss Per Share

Basic earnings per share does not include dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution of securities that could share in the earnings of an entity. Dilutive securities are not included in the weighted average number of shares when inclusion would be anti-dilutive. Due to the net losses for the years ended September 30, 2016 and 2015, basic and diluted loss per common share were the same, as the effect of potentially dilutive securities would have been anti-dilutive.

As of September 30, 2016 and 2015, there were total shares of 18,064,483 and 42,492,512, respectively, issuable upon conversion of notes payable, exercise of warrants and options that were not included in the earnings per share calculation as they were anti-dilutive.

Shipping and Handling

Shipping and handling costs associated with the shipment of products to the customer are recorded as costs of goods sold and totaled \$11,137 and \$11,495 for the years ended September 30, 2016 and 2015, respectively.

Advertising Costs

Advertising costs are charged to expense when incurred. Total advertising expense recognized during the years ended September 30, 2016 and 2015 were \$730 and \$11,950, respectively. Advertising expense is included in selling and marketing expenses on the accompanying consolidated statements of operations.

Stock-Based Compensation

All share-based payments to employees, including grants of employee stock options, are expensed based on their estimated fair values at grant date, in accordance with ASC 718. Compensation expense for stock options is recorded over the vesting period using the estimated fair value on the date of grant, as calculated using the Black-Scholes model. We classify all share-based awards as equity instruments and recognize the vesting of the awards ratably over their respective terms.

Recent Accounting Pronouncements

There have been no recently issued accounting pronouncements that have had or are expected to have a material impact on the Company's financial statements.

Note 2 - Going Concern

The Company has incurred losses since inception and requires additional funds for future operating activities. The Company's selling activity has not reached a level of revenue sufficient to fund its operating activities. These factors create an uncertainty as to how the Company will fund its operations and maintain sufficient cash flow to operate as a going concern. The combination of these factors, among others, raise substantial doubt about the Company's ability to continue as a going concern.

The Company's ability to meet its cash requirements in the next year is dependent upon obtaining additional financing and achieving improved sales levels. If this is not achieved, the Company may be unable to obtain sufficient cash flow to fund its operations and obligations, and as a result there is substantial doubt the Company will be able to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, and accordingly, do not include any adjustments relating to the recoverability and classification of recorded asset amounts; nor do they include adjustments to the amounts and classification of liabilities that might be necessary should the Company be unable to continue operations or be required to sell its assets.

Note 3 - Property and Equipment, Net

The following represents a summary of our property and equipment:

	September 30,	
	2016	2015
Manufacturing equipment	\$ 61,500	\$ 61,500
Office furniture and equipment	21,678	21,678
	83,178	83,178
Less: accumulated depreciation	(79,036)	(69,108)
	<u>\$ 4,142</u>	<u>\$ 14,070</u>

Depreciation expense was \$9,928 and \$20,968 for the years ended September 30, 2016 and 2015, respectively.

Note 4 - Convertible Notes Payable

Convertible notes payable consist of the following:

	September 30,	
	2016	2015
8.00% note payable, due August 22, 2012, convertible into common stock at \$.50 per share, interest payments are due at maturity, unsecured, in default.	\$ 5,000	\$ 5,000
Less current portion	(5,000)	(5,000)
	<u>\$ -</u>	<u>\$ -</u>

Note 5 - Notes Payable to Former Officer

Notes payable to a former officer consists of the following:

	September 30,	
	2016	2015
Note payable bearing interest at 0.27%, due August 1, 2016, interest due at maturity, unsecured	\$ 8,788	\$ 47,500

The Company has a note payable with an original principal balance of \$47,500 due to a former officer, which was due on August 1, 2016, is unsecured and carries an interest rate of 0.27%. On December 5, 2013 the Company revised the terms of the Note calling for four equal payments to begin on November 1, 2015 and ending August 1, 2016. As part of this revision, the interest rate was reduced from 2% to 0.27%. On August 1, 2016, the Company defaulted on the final payment due. At the end of September, the Company made a partial payment, of which \$3,087 was applied to principal, leaving a balance due of \$8,788, which remains in default.

Note 6 - Convertible Notes Payable to Related Parties

Convertible notes payable to related parties consist of the following:

	September 30,	
	2016	2015
12% note payable net of unamortized debt discount of \$204,470 and \$0, at September 30, 2016 and 2015, respectively, due September 30, 2017, convertible to common stock at \$.08 per share, interest payments are due monthly and may be made in common stock with a conversion price of \$.05 per share. Debt is secured by substantially all of the assets of the Company.	\$ 301,530	\$ 3,206,000
	20,000	20,000

8.00 % note payable due August 26, 2012, convertible to common stock at \$.50 per share, interest payments are due at maturity, unsecured, in default.

Less current portion

321,530	3,226,000
(321,530)	(20,000)
<u>\$ -</u>	<u>\$ 3,206,000</u>

Interest expense on the convertible notes payable to related parties (including amortization of debt discount of \$95,530 and \$1,901,341, respectively) was \$990,757 and \$2,959,899 for the years ended September 30, 2016 and 2015, respectively. Interest expense on the line of credit was settled via the issuance of 7,976,581 shares stock during the year ended September 30, 2016.

On August 31, 2015, the Company entered into an allonge to the convertible note to related parties through which the maturity date was extended by two years to September 30, 2017. In consideration for this extension, the Company granted 3,500,000 common stock warrants. The modification was accounted for as an extinguishment and the Company recorded a loss on extinguishment of debt of \$392,945 based on the fair value of the warrants. The fair value of the warrants was estimated using a Black Scholes model on the following assumptions:

Expected stock price volatility	28.96%
Expected dividend yield	0.00%
Risk-free interest rate	1.54%
Warrant term	10 years

On January 22, 2016, the Company entered into an Allonge to the convertible note held by our primary debt holder by which our line of credit was increased by \$200,000 and the conversion price of the outstanding principal balance was adjusted to \$.08 from \$.10. In accordance with ASC 470-50, the Company evaluated the modification of the debt under the terms of the newest allonge and determined the revised terms resulted in an extinguishment of debt. Accordingly, the difference between the reacquisition price of the debt and the net carrying amount of the extinguished debt was recognized in current income. A loss in the amount of \$1,122,100 was recorded on the debt extinguishment.

On July 28, 2016, the Company entered into an Allonge to the convertible note held by our primary debt holder by which our line of credit was increased by \$100,000 and we issued a five-year warrant for the purchase of 2,000,000 shares of our common stock at \$.05 per share. A loss in the amount of \$108,140 was recorded on the debt extinguishment.

On September 22, 2016, the Company received a conversion notice from our primary debt holder to convert \$3,000,000 of the note to shares of common stock. This resulted in the issuance of 65,934,066 shares of common stock, and the recognition of a \$296,703 loss on debt extinguishment.

Note 7 - Related Party Transactions

As detailed in Notes 5 and 6, the Company has a note payable to its former President, a convertible note payable to a former advisory board member and another convertible note with an entity that owns a majority of our outstanding shares.

As disclosed in Note 9, on March 8, 2016, the Company granted a total of 583,333 stock options to officers and a Board member.

During the years ended September 30, 2016 and 2015, the Company borrowed \$300,000 and \$498,000, respectively, against the convertible secured note and issued 7,976,581 and 7,277,533 shares of stock, respectively, in payment of interest on the convertible note.

The Company recorded expenses of \$78,534 and \$87,500 during the years ended September 30, 2016 and 2015 for fees due to a company owned by its CFO for her services as CFO. On September 26, 2016, our CFO agreed to convert \$12,760 of

outstanding amounts due to 163,595 shares of common stock. Additionally, the Company granted options to acquire 100,000 shares of common stock to its CFO directly during the year ended September 30, 2016.

The Company recorded expenses of \$119,784 and \$15,624 during the years ended September 30, 2016 and 2015 for fees due to a company owned by its President for his services as President. On September 26, 2016, our President agreed to convert \$33,852 of outstanding amounts due to 434,000 shares of common stock. Additionally, the Company granted options to acquire 500,000 shares of common stock to its President directly during the year ended September 30, 2015.

On September 26, 2016, our CEO agreed to convert \$34,231 of outstanding amounts due to 438,856 shares of common stock.

During the years ended September 30, 2016 and 2015, the Company paid \$663 and \$0 in cash for interest on related party debt.

Note 8 - Income Taxes

The Company's provision for income tax (benefit) expense from operations consists of the following:

	For the years ended September 30,	
	2016	2015
Current:		
Federal and State	\$ -	\$ -
Deferred:	(170,000)	1,794,000
Change in valuation allowance	170,000	(1,794,000)
Recognized tax benefit	<u>\$ -</u>	<u>\$ -</u>

The following table summarizes the significant differences between the U.S. federal statutory tax rate and the Company's effective tax rate for financial statement purposes for the years ended September 30, 2016 and 2015:

	For the years ended September 30,	
	2016	2015
U.S. federal statutory tax rate	34%	34%
State taxes	4.612%	4.612%
Change in valuation allowance	46.931%	(38%)
Non-deductible items	(85.5%)	(0.612%)
Totals	<u>0%</u>	<u>0%</u>

The tax effects of temporary differences that give rise to deferred tax assets and liabilities as of September 30, 2016 and 2015 are summarized as follows:

	For the years ended September 30,	
	2016	2015
Net operating loss carryforwards	\$ 14,160,000	\$ 13,990,000
Valuation allowance	(14,160,000)	(13,990,000)
Deferred tax assets, net	<u>\$ -</u>	<u>\$ -</u>

Note 9 - Commitments and Contingencies

On December 22, 2011, the Company entered into a distribution agreement that provides for the issuance of common stock warrants, with an expiration date of 3 years, for the purchase of the Company's common stock in an amount equal to 15% of the total products purchased by the distributor from the Company at the invoice price against the previous year's purchases of paid invoices. The warrant price will be equal to the closing price of the Company's stock price at the anniversary date of the agreement. As discussed in Note 10, per this agreement the Company issued a three-year warrant to purchase 145,510 shares at \$.13 on December 22, 2014. Additionally, the Company issued another three-year warrant to purchase 252,124 shares at \$.08 on December 22, 2015. The Company recorded the fair value of the warrants, totaling \$6,858 and \$3,993 for the years ended September 30, 2016 and 2015, respectively, as consulting fees.

The Company is in default on a convertible note payable totaling \$5,000 and a convertible note payable to a related party totaling \$20,000. The Company has attempted to communicate with the note holders to request extensions or conversion, but has been unsuccessful in doing so. The full balance on these notes are included in current liabilities.

As discussed in Note 4, the Company is in default on a note payable to a former officer. The principal balance due of \$8,788 as of September 30, 2016 is recorded in current liabilities.

The Company entered into an office lease agreement commencing June 1, 2014 and expiring August 31, 2017. As part of the lease agreement, a concession of the first three months' rent was provided. Total rent to be paid over the course of the lease is being expensed ratably over the period of the entire lease, creating a deferred rent liability of \$2,487 as of September 30, 2016. Rent expense was \$26,530 and \$26,517 for the years ended September 30, 2016 and 2015, respectively. Future minimum lease payments under this agreement total \$25,703 for 2017.

On July 23, 2014, the Company entered into an asset acquisition agreement. The agreement includes a liquidated damages clause in the amount of \$20,000 should the Company not move forward with product development within 12 months of the agreement date. This amount is reflected in accrued expenses on the Company's balance sheet as of September 30, 2016.

The Company sells the majority of its products through a distributor. The Company warrants to the distributors that the product will be free from defects in material and workmanship. The Company has determined its product warranty to be immaterial at September 30, 2016 and 2015. The likelihood that the Company's estimate of the accrued product warranty claims will materially change in the near term is considered remote.

Note 10 - Stockholders' Deficit

Common Stock

The following is a summary of common stock issuances for the years ended September 30, 2015 and 2016.

	Number of Shares of Common Stock
Balance at September 30, 2014	62,256,379
Issuance of stock for cash (1)	2,100,000
Exchange of shares for interest expense (2)	7,277,533
Exchange of shares for services (3)	498,271
Shares issued for conversion of accounts payable (4)	78,100
Balance at September 30, 2015	72,210,283
Issuance of stock for cash (5)	817,500
Exchange of shares for interest expense (6)	7,976,581
Exchange of shares for services (7)	1,312,697
Shares issued for conversion of notes payable (8)	65,934,066
Balance at September 30, 2016	148,251,127

(1) On March 9, 2015, the Company sold 250,000 shares for \$50,000 through a private placement.

Between August 11, 2015 and September 4, 2015, the Company sold 1,850,000 shares for \$185,000 through private placements.

(2) During the year ended September 30, 2015, the Company issued 7,277,533 shares of stock in payment of interest totaling \$363,877 on the primary debt holders' convertible note.

(3) During the year ended September 30, 2015, the Company issued 498,271 shares of common stock for services. The shares were valued at the average trading price over the period of service, which approximated fair value, in the amount of \$86,001.

(4) On July 9, 2015 the Company issued 78,100 shares of stock to a vendor in satisfaction of accounts payable totaling \$19,524.

(5) During the year ended September 30, 2016, the Company sold 527,500 shares for \$75,500 through private placements. Additionally, the Company issued 290,000 shares of common stock that had been purchased via stock purchase agreements, with monies received in the prior year.

(6) During the year ended September 30, 2016, the Company issued 7,976,581 shares of stock in payment of interest totaling \$398,829 on the primary debt holders' convertible note.

(7) During the year ended September 30, 2016, the Company issued 1,312,697 shares of common stock for services. The shares were valued at the average trading price over the period of service, which approximated fair value, in the amount of \$134,044.

(8) As disclosed in Note 6, on September 22, 2016, the Company received a conversion notice from our primary debt holder to convert \$3,000,000 of the note to shares of common stock. This resulted in the issuance of 65,934,066 shares of common stock.

Warrants:

	Common Shares Issuable Upon Exercise of Warrants	Exercise Price of Warrants	Date Issued	Expiration Date
Balance of Warrants at September 30, 2014	717,492			
Issued per distribution agreement (1)	145,510	\$0.13	12/22/2014	12/22/2017
Issued under a private placement memorandum (2)	750,000	\$0.25	8/12/2015	8/15/2016
Issued under a private placement memorandum (2)	125,000	\$0.25	8/19/2015	8/15/2016
Issued under a private placement memorandum (2)	50,000	\$0.25	9/8/2015	8/15/2016
Stockbridge issued as part of convertible agreement (3)	3,500,000	\$0.10	8/31/2015	8/31/2020
Expired warrants	<u>(300,000)</u>			
Balance of Warrants at September 30, 2015	4,988,002			
Issued per distribution agreement (1)	252,124	\$0.08	12/22/2015	12/22/2018
Issued under a private placement memorandum (2)	50,000	\$0.25	12/3/2015	12/3/2017
Issued under a private placement memorandum (2)	50,000	\$0.25	12/14/2015	12/14/2017
Issued under a private placement memorandum (2)	50,000	\$0.25	1/28/2016	1/28/2018
Stockbridge issued as part of convertible agreement (3)	2,000,000	\$0.05	7/28/16	7/28/2021
Expired warrants	<u>(1,150,464)</u>			
Balance of Warrants at September 30, 2016	<u><u>6,239,662</u></u>			

(1) As discussed in Note 9, on December 22, 2014, the Company issued a three-year warrant at \$.13 to purchase 145,510 shares of stock per a distribution agreement. Additionally, on December 22, 2015, the Company issued a three-year warrant at \$.08 to purchase 252,124 shares of stock under the same agreement.

(2) During the years ended September 30, 2016 and 2015, the Company issued warrants to purchase 150,000 and 925,000 shares of common stock, respectively, at \$0.25 as part of stock subscription agreements.

(3) As discussed in Note 6, on August 31, 2015, the Company issued a five-year warrant to our primary debt holder for the extension of the maturity date on the line of credit. The Company recorded the fair value of the warrants, totaling \$392,945, as a loss on extinguishment of debt for the year ending September 30, 2015.

On July 28, 2016, the Company issued a five-year warrant to our primary debt holder for an increase in our line of credit. A loss in the amount of \$108,140 was recorded on the debt extinguishment.

The following is a summary of the Company's warrant activity for the years ended September 30, 2016 and 2015:

	Warrants	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life in Years
Balance of Warrants at September 30, 2014	717,492	\$0.43	1.35
Granted	4,570,510	\$0.13	4.02
Exercised	-		
Expired	<u>(300,000)</u>	\$0.41	
Balance of Warrants at September 30, 2015	4,988,002	\$0.16	3.75
Granted	2,402,124	\$0.07	4.33
Exercised	-		
Expired	<u>(1,150,464)</u>	\$0.33	
Balance of Warrants at September 30, 2016 - outstanding	<u>6,239,662</u>	\$0.09	3.90
Balance of Warrants at September 30, 2016 - exercisable	<u>6,239,662</u>	\$0.09	3.90

Stock Options:

On April 2, 2015, the Company entered into an agreement with an option holder through which his option to purchase 200,000 shares with an exercise price of \$.50, was cancelled and he was granted a new option to purchase the same number of shares at a reduced price of \$.10. The Company recognized an expense of \$3,640 in the year ended September 30, 2015 as a result of this stock option grant.

On August 17, 2015, the Company granted 500,000 stock options to a corporate officer. The options are exercisable at \$.25 per share with a ten year term. The options will vest equally over three years unless there is a change in control of the Company.

Between November 1, 2015 and March 1, 2016, the Company granted 271,978 stock options to a vendor. The options are exercisable at \$.25 per share with a ten year term. The options vested immediately.

On March 8, 2016, the Company granted 583,333 stock options to corporate officers and a board member. The options are exercisable at \$.15 per share with a ten year term. The options for the corporate officers will vest equally over three years unless there is a change in control of the Company, and the options for the board member vested immediately.

Due to the conversion of a note by our primary debt holder, and the related issuance of shares, as discussed in Note 6, the Company considered this a change of control, and as such, all stock options granted prior to that date are vested and have been fully expensed.

The Company determines the fair value of stock options issued on the date of grant using the Black-Scholes option-pricing model. The following assumptions were used for determining the fair value of the options granted during the years ended September 30, 2016 and 2015:

	For the year ended September 30,	
	2016	2015
Expected stock price volatility	32.96-33.53%	32.78-32.90%
Expected dividend yield	0.00%	0.00%
Risk-free interest rate	1.83-2.27%	1.92-2.16%
Option life	10.00 years	10.00 years
Stock-based compensation recognized	\$115,213	\$68,438
Unrecognized compensation expense to be recognized in future periods	\$0	\$75,116

We have recently become a public company and common stock transactions were too infrequent, therefore we could not practicably estimate the expected volatility of our own stock. Accordingly, we have substituted the historical volatility of a relevant comparable company that is publicly traded and does business within the industry we operate.

The following is a summary of stock option activity for the years ended September 30, 2016 and 2015:

	Number of Stock Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term in Years	Aggregate Intrinsic Value
Balance of Options at September 30, 2014	5,894,510	\$0.33	5.89	\$ (1,061,012)
Granted	700,000	\$0.21	10.00	(43,000)
Exercised	-	-	-	-
Forfeited/Cancelled	(1,200,000)	\$0.38	-	-
Balance of Options at September 30, 2015	5,394,510	\$0.27	6.15	\$ (485,506)
Granted	855,311	\$0.18	10.00	(39,578)
Exercised	-	-	-	-
Forfeited/Cancelled	(800,000)	\$0.36	-	-
Balance of Options at September 30, 2016	<u>5,449,821</u>	<u>\$0.27</u>	<u>7.17</u>	<u>\$ (1,117,213)</u>
Vested at September 30, 2016	5,449,821			

Note 11 - Concentrations

The Company generally sells through a limited number of large distributors. The Company invoices the distributors directly as opposed to the ultimate retail store. Consequently, the Company's sales are to a small number of customers. For the years ended September 30, 2016 and 2015, sales to two distributors was approximately 94% and 65%, respectively, of our total sales.

The Company's products are manufactured exclusively by a factory in China. The ability of the Company to meet product order deadlines would be significantly impacted if the factory were to permanently cease operations for reasons outside of our control.

Note 12 - Subsequent Events

Management has considered subsequent events through January 11, 2017, which is the date the financial statements were available for issuance.

ITEM 6. ISSUER'S BUSINESS, PRODUCTS, AND SERVICES

Date and State of Incorporation

The Issuer was incorporated in the State of Delaware as Crown Dynamics Corp, on June 15, 2010.

Primary and Secondary SIC Codes

Primary: 3843

Issuers Fiscal Year End Date

The Issuer's fiscal year end is September 30.

Business Operations

Business Summary

To date, we primarily engage in the development, manufacture and distribution of nasal breathing devices. The Company has a portfolio of patents all related to the nasal dilator-breathing device, both filtered and non-filtered, and its use as a primary delivery mechanism through the nasal passage of therapeutic essential oils. The Company targets prospective customers such as compassionate sleeping partners, individuals with chronic sinus issues, individuals that suffer from chronic sleep disorders and individuals with allergies throughout the United States, Canada, Asia and Europe. The Company utilizes information and current studies in the development and manufacture of our products in order to help promote the health benefits of improved breathing, particularly information regarding breathing and its impact on the human body, the effects of environmental factors, and the potential benefits provided by the strategic use of therapeutic essential oils. The Company is supported by a selective group of highly experienced doctors, engineers and scientists who provide advice and information on research topics relevant to the Company's business purpose.

Business Plan

Airware Labs is a leader in innovative breathing technology solutions and consumer product offerings that enhance breathing. Airware products provide consumers with safe and effective methods to control their own personal breathing environment. Our filtered product also contains 3M filtration media for allergy sufferers.

Airware Labs maintains an efficient and economic corporate structure, outsourcing manufacturing and distribution through key strategic partnerships. Airware manufactures all products in China through an exclusive partnership with a factory that manufactures Airware products. Airware's corporate headquarters are located in Scottsdale, Arizona and houses the management, sales and marketing teams.

In April of 2012, Airware entered into a strategic partnership with Quest Products, Inc. ("Quest"), whereby Quest will promote and distribute the AIR® product line. Quest Products, Inc. (www.questproductsinc.com) provides turnkey solutions to Consumer Products Group ("CPG") companies looking to develop their product's distribution and sales to all classes of trade. Quest works with varying sizes of CPG companies, from inventors and entrepreneurs beginning start-up brands, to large industry leading CPG manufacturers looking to expand their reach. Quest's unique core competencies allow them to create turnkey solutions and drive new and incremental opportunities in sales for their client partners. Quest's sales team works with food, drug, and mass retailers across the USA and Canada, including Wal-Mart, Target, CVS, and Walgreens. Quest was listed as one of the fastest growing companies four years in a row by INC. Magazine.

Quest was successful in placing the AIR® product line with many of the largest online retailers, including Walgreens.com, Amazon.com, Drugstore.com, Target.com and more. Quest has also been successful in placing AIR® products in approximately 7,300 Walgreens stores located in the United States and the Company continues to receive reorders from Walgreens. Quest is presently attempting to gain distribution in other retail chains.

In March of 2014, Airware entered into a Joint Venture ("JV") with Eastar Industries in China to act as the exclusive distributor for all Airware products with an initial focus on the AIR® filters product line. Eastar Industries, a subsidiary of Eastar Chemical Corporation, focuses on Eastar's pharmaceutical and health/beauty business for China and selected Southeast Asian countries. Eastar Industries licenses patented pharmaceuticals, medical devices and unique health/beauty products from U.S. and European companies for import to China and Southeast Asia through its local joint venture partner companies.

Airware will own 18% of the JV that is formed in Hong Kong. Initial launch of AIR® PM2.5 began in December of 2014 in response to the severe pollution issues burdening most of the tier 1 cities of China. The creation of the JV entity has been put on hold as Airware evaluates new distribution options in the Asian market. Given the poor air quality and high demand for discreet and effective personal filtration devices, Airware is exploring more aggressive strategies to market in this region.

In August 2015, Airware hired Dr. Dan Cohen to assume the role of President. Dr. Cohen is the former Founder, Chairman and CEO of CNS, Inc., parent company of Breathe Right. Dr. Cohen was the driving force behind the meteoric rise of Breathe Right nasal strips, acquiring the rights to manufacture and sell the product for the medical equipment company he founded in 1982. With the successful drive to achieve FDA approval for marketing of the largely unknown product and with all of the top ten pharmaceutical wholesalers on board, Cohen launched a legendary marketing effort to generate market awareness. His efforts created an outcry of domestic and international consumer demand that rocketed CNS sales to a 77% increase as the company took the public spotlight and was named Fortune magazine's fourth fastest growing company in the U.S. in 1996. In 2006, GlaxoSmithKline acquired Breathe Right for \$566 million.

Dr. Cohen is a board certified neurologist and an accomplished entrepreneur. In addition to CNS, Inc., he is also the co-founder of Round River Research Corporation and the inventor of patented technology used for stress reduction and personal development. Dr. Cohen holds numerous patents related to EEG signal processing, physiologic analysis algorithms and additional utility patents related to synchronized sound, vibration and electromagnetic fields and their effect on the body and mind.

Dr. Cohen believes the Airware Nasal filter to be the best product in the market and has engineered a strategic plan to enhance Airware's nasal filtration product line with a launch planned in 2016, which includes extensive PR, education and awareness of the product benefits and competitive advantages.

In December 2016, Airware entered into a distribution agreement with a third party that includes the current filtered product line in countries and channels that complement the current distribution program. The agreement includes an open order with forecasts and minimum sales to maintain distribution rights.

Business Opportunity & Product Solutions

In the US alone, there exists a multi-billion dollar market for health related breathing products. Many of these products are sold over-the-counter (OTC) and have been developed specifically to enhance nasal breathing, relieve symptoms of allergic rhinitis, reduce snoring and improve sleep. Air® products specifically target these segments of the OTC breathing products market.

The AIR® nasal dilator is made from FDA-approved, latex-free/adhesive-free hypoallergenic medical grade material and has passed both cytotoxicity and an intra-cutaneous reactivity testing. The product is discreet, positioned inside the nostrils, and gently expands the nasal valve regions of the nasal passages thus opening the nasal airway allowing for easier nasal breathing. Many snorers do so because they cannot effectively breathe through their nose. By opening up the nasal passages allowing for greater nasal airflow, users are able to close their mouths and thereby reduce or stop snoring. Improved nasal breathing as well as reduced snoring generally improves sleep too. Unlike nasal strips, whose sales exceed \$150M, the AIR® product can be worn all day and night in comfort, without significantly altering appearance.

AIR® nasal products are manufactured with or without 3M's Filtration Media depending on the whether the product is designed to enhance nasal breathing alone or in addition, filter the air of particulate matter including allergens and bacteria. AIR® Allergy with 3M Filtration Media captures a larger number, and smaller size of particles, preventing them from entering the body. This in turn helps with the prevention of allergy symptoms and infection gained through airborne illnesses. The product is worn discreetly inside the nose, allowing daytime or nighttime use.

The 3M™ Air Filter Media used in Air products is uniquely constructed of permanently charged engineered fibers. These high permanent electrostatic charges allow the fibers to better capture and hold sub-micron particles, allowing particles to be effectively captured throughout the depth of the media, rather than only on the upstream surface, creating a filter that captures both a smaller sized particle, as well as an increase in the number of particles collected. The use of this filter technology in the AIR® Allergy product is the first use of the technology in this format.

Products

Air® Allergy

Air® Allergy is a discreet personal filter that helps protect you from irritating airborne allergens. Air® Allergy fits just inside the nose and uses filtration media from 3M to help stop allergens before they enter your system. Air® Allergy is also lightly infused with a blend of premium therapeutic essential oils that is shown to help reduce the symptoms associated with allergies.

Breathe better. Feel better with Air® Allergy:

- Helps block airborne allergens like pollen, dust and pet dander
- Filtration media from 3M
- Easy to breathe through
- Drug-free
- Infused with an essential oil blend designed to reduce allergy symptoms
- Soft, comfortable and discreet
- Latex-free

Sleep/Snore

Air® Sleep/Snore provides instant, drug-free relief for congestion and snoring caused by nasal breathing difficulties. It fits discreetly and comfortably just inside the nose to gently open nasal passages and increase airflow. Air® Sleep/Snore is also infused with a calming lavender essential oil blend that is shown to help reduce congestion and promote restful sleep.

Breathe better. Sleep better with Air® Sleep/Snore:

- Instantly relieves nasal congestion
- Clinically proven to reduce snoring
- Infused with a calming lavender essential oil blend
- Drug-free and adhesive-free
- Soft, comfortable and discreet
- Latex-free

Competition

Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical companies, and generic drug companies that offer products similar to ours. Many of our potential competitors have substantially greater financial, technical, and human resources than we do, as well as greater experience in the discovery and development of products and the commercialization of those products. Our competitors' products may be more effective, or more effectively marketed and sold, than any products we may commercialize and may render our products obsolete or non-competitive before we can recover the expenses of their development and commercialization. We anticipate that we will face intense and increasing competition as new products enter the market and advanced technologies become available. However, we believe that our products offer key potential advantages over competitive products that could enable our products to capture meaningful market share from our competitors.

ITEM 7. ISSUER'S FACILITIES

The Issuer's principal offices are located at 7377 East Doubletree Ranch Road, Suite 260, Scottsdale, AZ on a lease that expires in August 2017. Rent is \$2,337 per month through the end of the lease term.

ITEM 8. OFFICERS, DIRECTORS, AND CONTROL PERSONS

A. Officers and Directors

Jeffrey Rassas	Chief Executive Officer and Director
Jessica Smith	Chief Financial Officer, Secretary and Treasurer
Dr. Daniel E. Cohen	President, Chief Medical Officer and Director
Ronald L. Miller Jr.	Director

B. Involvement in Certain Legal Proceedings

None of the officers, directors, promoters or control persons of the Issuer have been involved in the past five (5) years in any of the following:

- (1) A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and minor offenses);
- (2) The entry of an order, judgment, or decree, not subsequently reverse, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities or bank activities;
- (3) A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or
- (4) The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

C. Beneficial Shareholders

Security Ownership of Certain Beneficial Owners and Management

Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership	Percentage of Beneficial Ownership ⁽¹⁾
Directors and Officers:		
Jeffrey Rassas ICO (2) Hayjour Family Limited Partnership 12689 N 120 th Pl Scottsdale, AZ 85259	4,438,043	2.99%
Jessica Smith (3) 7377 E Doubletree Ranch Rd Suite 260 Scottsdale, AZ 85258	563,595	0.38%
Daniel Cohen (4) 7377 E Doubletree Ranch Rd Suite 260 Scottsdale, AZ 85258	934,000	0.63%
Ronald L. Miller, Jr. (5) 7377 E Doubletree Ranch Rd Suite 260 Scottsdale, AZ 85258	650,023	0.44%
All directors and officers as a group (4 people)	6,585,661	4.44%
Beneficial Shareholders greater than 5%		
Stockbridge Enterprises LP (6) 7377 E Doubletree Ranch Rd Suite 200 Scottsdale, AZ 85258	93,630,518	63.16%

- (1) Applicable percentage of ownership is based on 148,251,127 shares of common stock outstanding on January 11, 2017. Percentage ownership is determined based on shares owned together with securities exercisable or convertible into shares of common stock within 60 days of January 11, 2017, for each stockholder. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Shares of common stock subject to securities exercisable or convertible into shares of common stock that are currently exercisable or exercisable within 60 days of January 11, 2017, are deemed to be beneficially owned by the person holding such securities for the purpose of computing the percentage of ownership of such person, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Our common stock is our only issued and outstanding class of securities eligible to vote.
- (2) Jeffrey Rassas is the Company's CEO and Director. Mr. Rassas' beneficial ownership includes: 2,438,044 shares of restricted common stock and 1,999,999 shares issuable upon the exercise of stock options which have vested as of the date of this report.
- (3) Jessica Smith is the Company's CFO, Secretary and Treasurer. Ms. Smith's beneficial ownership includes: 163,595 shares of restricted common stock and 400,000 shares issuable upon the exercise of stock options, which have vested as of the day of this report.
- (4) Dr. Daniel Cohen is the Company's President and Director. Dr. Cohen's beneficial ownership includes: 434,000 shares of restricted common stock and 500,000 shares issuable upon the exercise of stock options, which have vested as of the day of this report.

- (5) Ronald L. Miller, Jr. is a Director of the Company. Mr. Miller's beneficial ownership includes 600,000 shares issuable upon exercise of stock options which have vested as of the day of this report and 50,023 total shares purchased in May 2014. Of these shares 21,250 were purchased by Windsor Westfield Management, LLC and 21,250 shares of common stock were purchased by Chickamauga Enterprises, L.P. Both companies are indirectly controlled by Mr. Miller. The remaining 7,523 shares are held directly by Mr. Miller.
- (6) Stockbridge Enterprises LP is an Arizona limited partnership controlled by Mitchell A. Saltz, Chairman and Managing Partner.

ITEM 9. THIRD PARTY PROVIDERS

Counsel:

None

Accountant or Auditor:

D, Brooks & Associates CPA's, P.A.
319 Clematis Street, Suite 318
West Palm Beach, FL 33401

ITEM 10. ISSUER CERTIFICATION

I, Jeffrey Rassas, certify that:

1. I have reviewed this annual disclosure statement of Airware Labs Corp.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly represent in all material respects the financial condition, results of operations and cash flows of the Issuer as of, and for, the periods presented in the disclosure statement.

Date: January 13, 2017

Signature: /s/ Jeffrey Rassas

Chief Executive Officer and Director